BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also offers diagnostic and biosensor screening tests; transdermal patches and oral dissolvable formulations; and development of psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.…
BioNxt Solutions Inc. Announces Non-Brokered Private Placement of Units
BioNxt Solutions (CNSX: BNXT) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 0.2400 CAD on 20 November 2026, down 68.8% over 52 weeks. Its 52-week range is 0.2250 CAD to 0.7800 CAD: the price is 69.2% below the high and 6.7% above the low.
Its market capitalisation is 32.65M CAD.
BioNxt Solutions reports return on equity of 75.0%.
Its debt exceeds its cash by 5.96M CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.